Key result
Only ~25% of surveyed dentists consult cardiologists before interrupting newer antiplatelet or anticoagulant therapies.
Why the study?
The attitude and perception of dentists in northern Jordan toward antiplatelet and anticoagulant agents in cardiovascular patients and their adherence to guidelines were not well described.
Cross-Sectional (n=128)
Yes
Dentists in northern Jordan have poor awareness of newer antiplatelet and anticoagulant agents and infrequently consult cardiologists before interrupting these medications, highlighting a need for targeted education.
Answers are grounded in this paper and cite their sources.
Jordanian dentists' anticoagulant practices may diverge from guidelines; hypothesis-generating and should not yet change clinical protocols.
OBJECTIVES: The aim of this study was to describe the attitude and perception toward antiplatelet/anticoagulant agents in patients with cardiovascular diseases among dentists in the northern district of Jordan and to compare the current practice of Jordanian dentists and the recently published guidelines regarding the management of patients taking antiplatelet/anticoagulant drugs before dental procedures. MATERIALS AND METHODS: This is a cross-sectional study conducted on dentists and dental interns working at the dental clinics in northern Jordan, including dental clinics at Jordan University of Science and Technology (JUST) and the private sector. The total sample size comprised of 128 subjects (78 dentists from JUST and 50 private practitioners). The participants were interviewed using a preformed questionnaire to assess their knowledge and perceptions regarding the antiplatelets and the anticoagulant agents. Almost both the participants from JUST (25.78%) and the private sector (24.22%) are consulting the cardiologists with similar frequencies before interrupting the treatment with the antiplatelet/anticoagulant agents. Participants who have clinical PhD qualifications are more aware of the recent clinical guidelines and the newest agents compared to others. CONCLUSIONS: The awareness regarding the newest antiplatelet/anticoagulant agents is poor among the dentists in northern Jordan. However, the majority (62.3%) of them realize the consequences of interrupting such treatments in patients with coronary stents. Unfortunately, only a quarter of the dentists are consulting the cardiologists before interrupting the treatment with the antiplatelet agents. Proper education, courses, and workshops should be performed to the dentists to improve their knowledge about this critical issue.
No takes yet. Share an insight, caveat, or question.
Ibdah et al. (2020) conducted a cross-sectional in Knowledge and perception of antiplatelet and anticoagulant agents (n=128). Survey on antiplatelet and anticoagulant agents was evaluated on Knowledge and perceptions regarding antiplatelets and anticoagulant agents (p=0.002). Awareness of the newest antiplatelet and anticoagulant agents is poor among dentists in northern Jordan, with only ~25% consulting cardiologists before interrupting treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: